These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1559 related articles for article (PubMed ID: 25074884)

  • 1. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
    J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer].
    He W; Cheng M
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2591-2598. PubMed ID: 28840704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review.
    Dong J; Su SY; Wang MY; Zhan Z
    J Exp Clin Cancer Res; 2010 Oct; 29(1):137. PubMed ID: 20969765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs.
    Li D; Li W; Xu L; Che Y; Cheng C
    Medicine (Baltimore); 2022 Dec; 101(50):e32169. PubMed ID: 36550917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
    Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
    Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
    PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia.
    Zhang XF; De-Sheng LV; Li M; Sun GE; Liu CH
    Indian J Cancer; 2017; 54(1):104-114. PubMed ID: 29199672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment.
    Xiao BK; Yang JY; Dong JX; Ji ZS; Si HY; Wang WL; Huang RQ
    Asian Pac J Cancer Prev; 2015; 16(7):2915-21. PubMed ID: 25854383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
    Yan H; Li Q; Wang W; Zhen H; Cao B
    Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis].
    Cao F; Zhang L; Wang S; Zhong D; Wang Y
    Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):146-54. PubMed ID: 25800570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis.
    Kong F; Wang C; Li X; Jia Y
    Front Pharmacol; 2021; 12():739843. PubMed ID: 34588988
    [No Abstract]   [Full Text] [Related]  

  • 17. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Feng F; Huang J; Wang Z; Zhang J; Han D; Wu Q; He H; Zhou X
    BMC Complement Med Ther; 2020 Jan; 20(1):3. PubMed ID: 32020869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
    Zhang TT; Wang RM; Yang Z; Chen GB
    Clin Transl Oncol; 2016 Jun; 18(6):576-81. PubMed ID: 26527033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
    Li D; Yao L; Xu L; Li W; Che Y
    Medicine (Baltimore); 2022 Dec; 101(48):e32164. PubMed ID: 36482605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.